Related Experiment Video
Updated: Feb 14, 2026
06:12
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
7.7K
HP-228 (Trega Biosciences Inc)
1Zen Bio Inc, 3200 Chapel Hill-Nelson Blvd, Suite 102, PO Box 12503, Research Triangle Park, NC 27709, USA. zenbio@mindspring.com
Idrugs : the Investigational Drugs Journal
|August 30, 2005
Summary
HP-228, a cytokine regulating agent, is in Phase II trials for post-surgical pain and inflammation. Development for diabetes, obesity, and chemotherapy toxicity has been discontinued.
Area of Science:
- Pharmacology
- Immunology
- Drug Development
Background:
- HP-228 is a cytokine regulating agent developed by Trega Biosciences.
- The drug was previously investigated for diabetes, obesity, and chemotherapy-induced toxicity.
Purpose of the Study:
- To evaluate HP-228 for managing post-surgical pain and inflammation.
- To assess the therapeutic potential of cytokine modulation in inflammatory conditions.
Main Methods:
- Phase II clinical trials were conducted.
- Patient outcomes related to pain and inflammation were monitored.
Main Results:
- HP-228 is currently undergoing Phase II trials for post-surgical pain and inflammation management.
- Development for other indications, including diabetes and obesity, has been ceased.
Conclusions:
- HP-228 shows promise in managing post-surgical pain and inflammation.
- Further research and development are ongoing for its application in pain management.
